E
Eugenio Donato di Paola
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 5
Citations - 1722
Eugenio Donato di Paola is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Imatinib & Pharmacodynamics. The author has an hindex of 4, co-authored 4 publications receiving 1701 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Allan T. van Oosterom,Ian Judson,Jaap Verweij,Sigrid Stroobants,Eugenio Donato di Paola,Sasa Dimitrijevic,Marc Martens,Andrew Webb,Raf Sciot,Martine Van Glabbeke,Sandra Silberman,Ole S. Nielsen +11 more
TL;DR: Impatinib at a dose of 400 mg twice daily is well tolerated during the first 8 weeks, side-effects diminish with continuing treatment, and it has significant activity in patients with advanced GISTs.
Journal ArticleDOI
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
Allan T. van Oosterom,Ian Judson,Jaap Verweij,Sigrid Stroobants,Herlinde Dumez,Eugenio Donato di Paola,Raphael Sciot,Martine Van Glabbeke,Sasa Dimitrijevic,Ole S. Nielsen +9 more
TL;DR: In this paper, a phase I study conducted by the EORTC Soft Tissue and Bone Sarcoma Group, 40 patients with advanced soft tissue sarcomas, most of whom had gastrointestinal stromal tumors (GISTs), received imatinib at doses of 400 mg q.i.d., 400 mg b.i., or 500 mg q i.d. Dose-limiting toxicities, including severe nausea, vomiting, edema and rash, were seen at the highest dose level; the maximum tolerated dose was therefore 400 mgb.i
Journal ArticleDOI
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group
Ian Judson,Peiming Ma,Bin Peng,Jaap Verweij,Amy Racine,Eugenio Donato di Paola,Martine Van Glabbeke,Sasa Dimitrijevic,Michelle Scurr,Herlinde Dumez,Allan T. van Oosterom +10 more
TL;DR: There was a trend towards increased imatinib clearance after chronic exposure over 12 months, and it is not yet clear whether this is a significant factor in the amelioration ofImatinib toxicity that occurs with time or is related to disease control.
Journal ArticleDOI
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Michael G Leahy,Isabelle Ray-Coquard,Jaap Verweij,Axel Le Cesne,Florence Duffaud,Pancras C.W. Hogendoorn,Camilla Fowst,Christine de Balincourt,Eugenio Donato di Paola,Martine Van Glabbeke,Ian Judson,Jean-Yves Blay +11 more
TL;DR: The study assessed the efficacy and safety of brostallicin, a new DNA minor groove binder, at a dose of 10mg/m2, intravenous every three weeks, in patients with advanced or inoperable soft tissue sarcoma (STS) and gastrointestinal stromal tumour (GIST) failing first line therapy.
Journal ArticleDOI
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
Pierfrancesco Tassone,Maria Teresa Di Martino,Mariamena Arbitrio,Lucia Fiorillo,Nicoletta Staropoli,Domenico Ciliberto,Alessia Cordua,Francesca Sidoti,Bernardo Bertucci,Angela Salvino,Mariangela Lopreiato,Fredrik Thunarf,O. Cuomo,Maria Cristina Zito,Simona Gualtieri,Caterina Riillo,F. A. Manti,Daniele Caracciolo,Vito Barbieri,Eugenio Donato di Paola,Pierosandro Tagliaferri +20 more
TL;DR: A 13-mer lock-nucleic acid (LNA) inhibitor of miR-221 with a full phosphorothioate (PS)-modified backbone was developed in this paper .